Evidence map›Paper›PMID 20013192›Full record

ReviewMethods in molecular biology (Clifton, N.J.)2010

Oxidized low-density lipoprotein.

Sampath Parthasarathy, Achuthan Raghavamenon, Mahdi Omar Garelnabi, Nalini Santanam

Registry-linked trialAbstract readReview
In one paragraph

Review in Methods in molecular biology (Clifton, N.J.), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04317287 (A Double-blind, Randomized, Placebo-controlled, Parallel Design Study to Evaluate the Effects of the Cardio Formulation on Oxidized LDL in Individuals Who Are Overweight to Mildly Obese and Otherwise Healthy), which is not on this map. Cited by 131 papers.

0numbers the graph read from it
0cells of the map it votes in
131citing papers in PubMed
11.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04317287 naterminatednot on this mapstarted 2019, after this paper: background citation

A Double-blind, Randomized, Placebo-controlled, Parallel Design Study to Evaluate the Effects of the Cardio Formulation on Oxidized LDL in Individuals Who Are Overweight to Mildly Obese and Otherwise Healthy

TypeinterventionalSponsorSupplement Formulators, Inc.Ran2019 to 2021Enrolled9ConditionsOxidized Low Density LipoproteinArmsCardio formulation, Placebo
3 · Its place in the literature

Who cites it

131 citing papers in PubMed, 333 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. The Potential of Superoxide Dismutase-RichInternational journal of molecular sciences · 2025
    Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Atherogenic Effect of Homocysteine, a Biomarker of Inflammation and Its Treatment.The International journal of angiology : official publication of the International College of Angiology, Inc · 2024
    Review
  17. Role of C-Reactive Protein, An Inflammatory Biomarker in The Development of Atherosclerosis and Its Treatment.The International journal of angiology : official publication of the International College of Angiology, Inc · 2024
    Review
  18. Review
  19. Lecithin and cardiovascular health: a comprehensive review.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2024
    Review
  20. Oxidized mRNA Lipid Nanoparticles forAdvanced functional materials · 2024
    Article

71 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 1 country.

Sampath ParthasarathyDivision of Cardiothoracic Surgery, The Ohio State University Medical Center, Columbus, OH, USA.
Achuthan Raghavamenon
Mahdi Omar Garelnabi
Nalini Santanam
Marshall University · USSouthern University and Agricultural and Mechanical College · USThe Ohio State University · USThe Ohio State University Wexner Medical Center · US

Funding

Oxidation Hypothesis--Paradoxes and PitfallsR01HL069038 · NHLBI · OHIO STATE UNIVERSITY · PI PARTHASARATHY, SAMPATH · 2002 to 2006
$1.8M
Oxidized Lipids in Cardiovascular DiseaseR01HL074239 · NHLBI · MARSHALL UNIVERSITY · PI SANTANAM, NALINI · 2004 to 2008
$1.8M
NHLBI NIH HHS HL-069038NHLBI NIH HHS HL-74239NHLBI NIH HHS HL74239NHLBI NIH HHS R01 HL069038NHLBI NIH HHS R01 HL074239
6 · The paper itself

Abstract

Oxidized low-density lipoprotein (Ox-LDL) has been studied for over 25 years. Numerous pro- and anti-atherogenic properties have been attributed to Ox-LDL. Yet, Ox-LDL has neither been defined nor characterized, as its components and composition change depending on its source, method of preparation, storage, and use. It contains unoxidized and oxidized fatty acid derivatives both in the ester and free forms, their decomposition products, cholesterol and its oxidized products, proteins with oxidized amino acids and cross-links, and polypeptides with varying extents of covalent modification with lipid oxidation products, and many others. It seems to exist in vivo in some form not yet fully characterized. Until its pathophysiological significance, and how it is generated in vivo are determined, the nature of its true identity will be only of classical interest. In this review, its components, their biological actions and methods of preparation will be discussed.

Indexed as

Lipoproteins, LDLOxidative StressAntioxidantsHumansLipid PeroxidationLipidsOxidantsOxidation-ReductionProteinsAntioxidantsLipidsLipoproteins, LDLOxidantsoxidized low density lipoproteinProteins

Identifiers

PMID20013192
PMCPMC3315351
OpenAlexW1597938677

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.